Safety and effectiveness of sodium stibogluconate and paromomycin combination for the treatment of visceral leishmaniasis in eastern Africa: results from a pharmacovigilance programme

by Kimutai R, Musa AM, Njoroge S, Omollo R, Alves F, Hailu A, Khalil EAG, Diro E, Soipei P, Musa B, Salman K, Ritmeijer K, Chappuis F, Rashid J, Mohammed R, Jameneh A, Makonnen E, Olobo J, Okello L, Sagaki P, Strub N, Ellis S, Alvar J, Balasegaram M, Alirol E, Wasunna M.

Clinical Drug Investigation, January 2017

WorldLeish 6

6th World Congress on Leishmaniasis

May 16-20, 2017
Toledo, Spain
The WHO ColIaborating Centre for Leishmaniasis at the Instituto de Salud Carlos III, Madrid and the Drugs for Neglected Diseases initiative, Geneva have joined efforts to co-organize the WorldLeish-6 Congress.

NTD Summit 2017

April 19-22, 2017
Geneva, Switzerland
DNDi will be participating at the event.

ISNTD Festival

International Society for Neglected Tropical Diseases Festival

February 23, 2017
London, United Kingdom
James Arkinstall, DNDi‘s Head of Communications & Advocacy, presented on the fundraising campaign for sleeping sickness with the Huffington Post.

The 7th KASH Conference

KEMRI Annual Scientific and Health Conference

February 8-10, 2017
Nairobi, Kenya
DNDi participated at the event.

Prince Mahidol Award Conference 2017

Assessing the health of vulnerable population for an inclusive society

January 29-February 3, 2017
Bangkok, Thailand
Marc Lallemant, Head of Paediatric HIV Program at DNDi spoke at the event and Jean-Michel Piedagnel, Head of DNDi South East-Asia Regional Office hosted a Q&A session.

2016 in Review

Our staff, partners, and stakeholders share their highlights from 2016.

 

Renewed commitment of the German Government to neglected diseases

KfW, on behalf of the Federal Ministry of Education and Research (BMBF), grants EUR 10 Million to DNDi

DNDi has been awarded EUR 10 million towards the development of treatments against sleeping sickness, visceral leishmaniasis, Chagas disease, and filarial diseases. The grant will be starting this year and be disbursed over five years.

Essential medicines for universal health coverage

by Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de Joncheere CP, Ewen MA, Gyansa-Lutterodt M, Jing S, Luiza VL, Mbindyo RM, Möller H, Moucheraud C, Pécoul B, Rägo L, Rashidian A, Ross-Degnan D, Stephens PN, Teerawattananon Y, ’t Hoen EFM, Wagner AK, Yadav P,  Reich MR.

The Lancet, November 2016